Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, September 19, 2023
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
[ Tue, Sep 19th 2023
] - WOPRAI
Mon, September 18, 2023
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
[ Mon, Sep 18th 2023
] - WOPRAI
Brian Abrahams Upgraded (BCRX) to Buy and Increased Target to $10 on, Sep 18th, 2023
Brian Abrahams of RBC Capital, Upgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Buy and Increased Target from $9 to $10 on, Sep 18th, 2023.
Brian has made no other calls on BCRX in the last 4 months.
There are 4 other peers that have a rating on BCRX. Out of the 4 peers that are also analyzing BCRX, 0 agree with Brian's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Brian
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $30 on, Friday, August 4th, 2023
- Maury Raycroft of "Jefferies" Upgraded from Hold to Strong Buy and Held Target at $11 on, Friday, August 4th, 2023
- Serge Belanger of "Needham" Reiterated at Strong Buy with Decreased Target to $12 on, Thursday, August 3rd, 2023
- Tazeen Ahmad of "B of A Securities" Upgraded from Hold to Strong Buy and Held Target at $10 on, Thursday, July 13th, 2023
